Brief: Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors at SNO Pediatric Conference
29/05/2025 14:10
May 29 (Reuters) - Lantern Pharma Inc LTRN.O: LANTERN PHARMA'S LP-184 SHOWS PROMISING IN VIVO ACTIVITY IN ATYPICAL TERATOID RHABDOID TUMORS (ATRT) AT SNO PEDIATRIC CONFERENCE, FURTHER VALIDATING RARE PEDIATRIC DISEASE DESIGNATION AND PATHWAY TO CLINICAL TRIALS Source text: ID:nBw7htjnQa Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview